Form 8-K Cara Therapeutics, Inc. For: May 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'
May 23, 2018 12:44 PM EDTH.C. Wainwright raised its price target on Cara Therapeutics (NASDAQ: CARA) to $24.00 (from $22.00) while maintaining a Neutral rating.
... MoreCara Therapeutics (CARA) PT Raised to $20 at Stifel Following Vifor-Fresenius JV
May 23, 2018 11:01 AM EDTStifel raised its price target on Cara Therapeutics (NASDAQ: CARA) to $20.00 (from $17.00) while maintaining a Buy rating after the company announced a licensing arrangement with Vifor Fresenius Medical Care Renal Pharma (VFMCRP)a joint venture between Vifor Pharma (market leading provider of renal drugs) and... More
